This test requires professional lab infrastructure and staff and must be ordered and administered by medical professionals. The test cannot be performed by private individuals and we do not sell the kits to such subjects. If you suspect you are infected with SARS-CoV-2, please contact your healthcare provider.

For detection of neutralizing antibodies in plasma/serum, vaccine development, screening drugs and antibodies against COVID-19.

The ImmunoDiagnostics SARS-COV2 S1RBD-ACE2 Binding Assay is designed to measure the interaction between the receptor binding domain of the viral spike glycoprotein (S1RBD) with the cell surface receptor ACE2. The assay can detect the neutralizing antibodies in human plasma or serum which inhibit the S1RBD-ACE2 interaction and can also be used for screening the inhibitors and potential drugs and vaccine development.

The SARS-COV2 S1RBD-ACE2 Binding Assay is a competitive ELISA assay, which can mimic the virus neutralization process. 96-well plates are coated with SARS-CoV-2 S1RBD protein that captures neutralization antibodies or compounds which bind to SARS-CoV-2 S1RBD protein in the sample. After washing away unbound materials, captured neutralization antibodies or compounds can block the binding between horseradish peroxidase (HRP) conjugated recombinant human ACE2. After washing step, the chromogenic substrate 3,3’,5,5’-tetramethylbenzidine (TMB) is added. Color reaction is stopped by 2M H2SO4. The inhibitory efficiency of neutralization antibodies or compounds against SARS-CoV-2 S1RBD captured inside the wells is inversely proportional to the color density generated in the coupled oxidation-reduction reaction.

Each kit is sufficient for 96 tests and contains the following components:

One aluminum pouch with a Microwell plate (12 strips of 8 wells each) coated with SARS-CoV-2 S1RBD protein, sealed. The microwell strips can be used separately.

10 × Wash buffer, 1 x 40 ml

5 × Assay buffer, 1x 20 ml

100 × Detection reagent: HRP-conjugated human ACE2, 1 x 0.12 ml

10 x Positive control A (strong): An anti-S1RBD monoclonal antibody, 1 x 22 ul

10 x Positive control B (medium), An anti-S1RBD monoclonal antibody, 1x 22 ul

Substrate solution, 1 x 12 ml, ready for use

Stop solution, 1 x 12 ml, ready for use

Blank control, 1 ml, ready for use

Results in under 2.0 hours

Evaluation of COVID-19 vaccine effectiveness

Detection of neutralizing antibodies against SARS-CoV-2